Risks and side effects in the medical management of benign prostatic hyperplasia
Prostate International · 2024-06 · 12 (2) · 57-64
DOI: 10.1016/j.prnil.2023.11.004 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Prostate International, 2024-06. Verfasst von Abdulghafour Halawani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Benign prostatic hyperplasia affects up to 80% of men in their lifetime. It causes bladder outflow obstruction, leading to lower urinary tract symptoms, which can have a large impact on quality of life. Lifestyle modifications and pharmacotherapy are often offered as first-line treatments for patients. These include alpha blockers, 5-alpha-reductase inhibitors, phosphodiesterase-5 inhibitors, anticholinergics, B3-agonists, and desmopressin. While often well tolerated, these pharmacotherapies do have significant side effects, which both clinicians and patients should understand and discuss in order to make an informed treatment decision among alternatives. The purpose of this review is to provide a current overview of the risks and side effects of commonly used medications in benign prostatic hyperplasia management.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, King Abdulaziz University, Jeddah, Saudi Arabia.
- Department of Urological Sciences, University of British Columbia, Stone Centre at Vancouver General Hospital, Vancouver, British Columbia, Canada.
- University of Alberta, Edmonton, Alberta, Canada.
- Vancouver Prostate Centre, Vancouver, British Columbia, Canada.
Zitieren
APA
Halawani, A., Paterson, R., Zhong, T., Du, K., Ren, R., & Forbes, C. M. (2024). Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate International, 12(2), 57-64. https://doi.org/10.1016/j.prnil.2023.11.004
Vancouver
Halawani A, Paterson R, Zhong T, Du K, Ren R, Forbes CM. Risks and side effects in the medical management of benign prostatic hyperplasia. Prostate International. 2024;12(2):57-64. doi:10.1016/j.prnil.2023.11.004
BibTeX
@article{Halawani2024,
author = {Halawani, Abdulghafour and Paterson, Ryan and Zhong, Tianshuang and Du, Katie and Ren, Runhan and Forbes, Connor M},
title = {Risks and side effects in the medical management of benign prostatic hyperplasia},
journal = {Prostate International},
year = {2024},
volume = {12},
number = {2},
pages = {57--64},
doi = {10.1016/j.prnil.2023.11.004}
}
EUVIMED